Development Advancing to Verification and Testing Phase
Aims to Future-Proof Design, Lower Componentry Costs, and Improve Manufacturing
NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, has announced that its third-party contractor has completed the design phase for the development of the Company’s next generation PainShield® and UroShield® devices.
Key Highlights
- Design Phase Completion: The third-party contractor has successfully completed the design phase in December 2024.
- Prototypes Delivered: Prototypes of the next-generation PainShield and UroShield devices were delivered on-time and within budget.
- Moving Forward: The Company is now eager to move forward to the verification and testing phase for further validation and testing.
Design Updates Include
Additional Mode of Therapy
The new design includes an additional mode of therapy that aims to enhance user experience and improve efficacy. This enhancement is expected to provide better outcomes for patients using PainShield and UroShield devices.
Future-Proofing and Optimization of Componentry
The design has been updated to ensure that its current components will remain readily available throughout the manufacturing and commercialization process. This future-proofing measure aims to minimize production delays and costs associated with sourcing new components.
Streamlining the Software
Efforts have been made to simplify and optimize the software for better performance and ease of use. The streamlined software is expected to improve user experience, reduce training time, and enhance overall efficiency.
Enhancements to User Interface
The actuator cable has been redesigned to feature USB-C connectors, providing a more convenient and efficient connection process. Additionally, a single lead will now be used for the UroShield model, simplifying device setup and reducing complexity.
Improvements to Design
The new design incorporates improvements that promote cost-effective production and regulatory compliance. These enhancements aim to reduce manufacturing costs, minimize waste, and ensure seamless integration with existing infrastructure.
Moving Forward
The Company is moving to the next phase of development, which will involve further validation and testing based on feedback and protocols received to date. This phase aims to verify the design’s performance, safety, and efficacy before commercialization.
About NanoVibronix, Inc.
NanoVibronix, Inc. (NASDAQ: NAOV) is a medical device company headquartered in Tyler, Texas, with research and development in Nesher, Israel. The Company focuses on developing medical devices utilizing its patented low-intensity surface acoustic wave (SAW) technology.
Proprietary Technology
The proprietary technology allows for the creation of low-frequency ultrasound waves that can be utilized for various medical applications, including disruption of biofilms and bacterial colonization, as well as pain relief. The devices can be administered at home without continuous assistance from medical professionals.
Product Line
The Company’s primary products include PainShield and UroShield, which are portable devices suitable for administration at home or in any care setting. Additional information about NanoVibronix is available on their website: www.nanovibronix.com.
Forward-Looking Statements
This press release contains forward-looking statements that may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," or similar expressions. These statements are subject to certain risks and uncertainties that could cause actual results to differ from those expressed in the forward-looking statements.
Risk Factors
The Company’s filings with the Securities and Exchange Commission ("SEC") include detailed information about the risk factors that may affect the realization of forward-looking statements. Investors and security holders are urged to read these documents free of charge on the SEC’s website at: http://www.sec.gov.
Conclusion
The development of next-generation PainShield and UroShield devices by NanoVibronix, Inc. is an exciting step forward in medical technology. The new design features improvements that aim to enhance user experience, improve efficacy, and promote cost-effective production.
Investor Contact
For more information about the Company’s progress or to inquire about investment opportunities, please contact:
Brett Maas
Managing Principal, Hayden IR, LLC
brett@haydenir.com
(646) 536-7331
